MTOR and cancer: For example, Corominas-Faja et al. [2] used OSKM to reprogram the MCF-7 human breast cancer cells into SOX2-overexpressing cancer stem cell (CSC)-like cells that exhibit activated mammalian target of rapamycin (mTOR) kinase activity.